<DOC>
	<DOCNO>NCT01644253</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy TRU-016 administer combination rituximab obinutuzumab , combination idelalisib rituximab , combination ibrutinib patient chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Phase 1b Safety Efficacy Study TRU-016 Rituximab , Obinutuzumab , Idelalisib , Ibrutinib Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Diagnosis CLL 2008 IWCLL criterion Rai stage intermediate high risk CLL No prior therapy CLL Cohorts 1 , 3 4 . For Cohort 2 , 13 prior treatment . For Cohort 5 , patient must fail respond relapse 1 treatment regimen . For Cohort 6 , patient receive ibrutinib least 12 month , CR , cysteine 481 mutation detect . For Cohort 7 , patient receive ibrutinib stable disease cysteine 481 mutant clone present level &gt; 1 % . At least one follow criterion active disease require treatment : progressive splenomegaly and/or lymphadenopathy ; anemia thrombocytopenia due bone marrow involvement ; progressive lymphocytosis increase &gt; 50 % 2month period unanticipated doubling time le 6 month For Cohorts 1 , 3 4 , contraindication chemotherapy firstline therapy due patient age , comorbidity patient preference Age &gt; /= 18 year ECOG performance status &lt; /= 2 Life expectancy &gt; 6 month opinion Investigator Serum creatinine , total bilirubin , ALT/SGPT &lt; /= 2.0 x upper limit normal ANC &gt; /= 800/mm3 Platelets &gt; /= 30,000/mm3 For Cohorts 1 , 3 4 : Has receive treatment rituximab , alemtuzumab , ofatumumab chemotherapeutic agent CLL Has receive investigational therapy within 30 day first dose study drug Previous concurrent additional malignancy Clinically significant pulmonary dysfunction , active infection , prior allogeneic bone marrow transplant , active autoimmune disease Positive serology HIV hepatitis C Hepatitis B surface antigen hepatitis B core antibody positive Pregnant breastfeed Known current drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>previously untreated chronic lymphocytic leukemia</keyword>
</DOC>